Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity
Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718037/ |
| Summary: | Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been incremental progress in defining the minimal clinically important difference (MCID) of key disease manifestations and the view is largely that of the health care providers and not that of the person suffering the disease. This basic methodological work on the MCID should improve the efficiency and the clinical relevance of future trials and their design. |
|---|